Takeda Pharmaceutical Company

Takeda strikes $1B RNAi deal with Arrowhead Pharmaceuticals

  • by

The companies will partner on development and commercialization of ARO-AAT, Arrowhead’s Phase II RNA-interference drug for alpha-1 antitrypsin-associated liver disease, a rare genetic disorder. An analyst wrote that the deal makes sense given Takeda’s position in the AAT-augmentation therapy market.